Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Gastroenterology
Published in: BMC Gastroenterology 1/2009

Open Access 01-12-2009 | Research article

Tolllike receptor 4 (TLR4) polymorphisms in Tunisian patients with Crohn's disease: genotype-phenotype correlation

Authors: Lilia Zouiten-Mekki, Maher Kharrat, Sami Karoui, Mariem Serghimi, Monia Fekih, Samira Matri, Lamia Kallel, Jalel Boubaker, Azza Filali, Habiba Chaabouni

Published in: BMC Gastroenterology | Issue 1/2009

Login to get access

Abstract

Background

The immune responses to bacterial products through the pattern recognition receptor (PRR) play a pivotal role in pathogenesis of Crohn's disease. A recent study described an association between CD and some gene coding for bacterial receptor like NOD2/CARD15 gene and TLR4. In this study, we sought to determine whether TLR4 gene was associated with Crohn's disease (CD) among the Tunisian population and its correlation with clinical manifestation of the disease.

Methods

90 patients with CD and 80 healthy individuals are genotyped for the Asp299Gly and Thr399Ile polymorphisms by restriction fragment length polymorphism analysis.

Results

The allele and genotype frequency of the TLR4 polymorphisms did not differ between patients and controls. The genotype-phenotype correlation permitted to show that the Thr399Ile polymorphism was associated with early onset disease.

Conclusion

this study reported the absence of association between CD and TLR4 gene in the Tunisian population, but this gene could play a role in clinical expression of the disease.
Appendix
Available only for authorised users
Literature
1.
Cantor MJ, Nickerson P, Bernstein CN: The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease. Am J Gastroenterol. 2005, 100 (5): 1134-42. 10.1111/j.1572-0241.2005.40979.x.CrossRefPubMed
2.
Ahmad T, Tamboli PC, Jewell D: Clinical relevance of advances in Genetics and pharmacogenetics of IBD. Gastroenterology. 2004, 126: 1533-1549. 10.1053/j.gastro.2004.01.061.CrossRefPubMed
3.
Mathew CG, Lewis CM: Genetics of inflammatory bowel disease: progress and prospects. Hum Mol Genet. 2004, 13: R161-R168. 10.1093/hmg/ddh079.CrossRefPubMed
4.
Newmann B, Siminovitch KA: Recent advances in the genetics of inflammatory bowel disease. Curr Opin Gastroenterol. 2005, 21 (4): 401-7.
5.
Ogura Y, Bonen DK, Inohra N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirshner BS, Hanauer SB, Nunez G, Cho JH: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001, 411: 603-606. 10.1038/35079114.CrossRefPubMed
6.
Hugot JP, Chamaillard M, Wouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassul M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent Puig P, Gower Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G: Association of NOD 2 leucine repeat variants with susceptibility to Crohn's disease. Nature. 2001, 411: 599-603. 10.1038/35079107.CrossRefPubMed
7.
Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, Frenzel H, King K, Hasselmeyer A, MacPherson AJ, Bridger S, Van Deventer S, Forbes A, Nikolaus S, Lennard Jones JE, Foelsch UR, Krawczak M, Lewis C, Schreiber S, Mathew CG: Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet. 2001, 357: 1925-1928. 10.1016/S0140-6736(00)05063-7.CrossRefPubMed
8.
Bonen DK, Ogura Y, Nicolae DL: Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology. 2003, 124: 140-146. 10.1053/gast.2003.50019.CrossRefPubMed
9.
Inohara N, Ogura Y, Fontalba A: Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. 2003, 278: 5509-5512.
10.
Girardin SE, Boneca IG, Viala J: Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem. 2003, 278: 8869-8872. 10.1074/jbc.C200651200.CrossRefPubMed
11.
Fort MM, Mozaffarian A, Stover AG, Correia Jda S, Johnson Marsh S, McLeod HL: Crohn's disease: ethnic variation in CARD15 genotypes. Gut. 2003, 52: 770-10.1136/gut.52.5.770.CrossRef
12.
Zouiten-Mekki L, Zouali H, Boubaker J: CARD15/NOD2 in Tunisian population with Crohn's disease. Dig Dis Sci. 2005, 50 (1): 130-135. 10.1007/s10620-005-1290-0.CrossRefPubMed
13.
Inoue N, Tamura K, Kinouchi Y, Fukuda Y, Takahashi S, Ogura Y, Inohara N, Nunez G, Kishi Y, Koike Y, Shimosegawa T, Shimoyama T, Hibi T: Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology. 2002, 123: 86-91. 10.1053/gast.2002.34155.CrossRefPubMed
14.
Yamazaki K, Takazoe M, Tanaka T, Kazumori T, Nakamura Y: Absence of mutation in the NOD2/CARD15 gene among 483 Japanese patients with Crohn's disease. J Hum Genet. 2002, 47: 469-472. 10.1007/s100380200067.CrossRefPubMed
15.
Leong RW, Armuzzi A, Ahmad T, Wong ML, Tse P, Jewell DP, Sung JJ: NOD2/CARD15 gene polymorphisms and Crohn's disease in the Chinese population. Aliment Pharmacol Ther. 2003, 17: 1465-1470. 10.1046/j.1365-2036.2003.01607.x.CrossRefPubMed
16.
Croucher PJ, Mascheretti S, Hampe J, et al: Haplotype structure and association to Crohn's disease of CARD15 mutations in two ethnically divergent populations. Eur J Hum Genet. 2003, 11: 6-16. 10.1038/sj.ejhg.5200897.CrossRefPubMed
17.
Riis LB, Wolters F, Solberg C: Regional differences in the prevalence of single nucleotide polymorphisms in CARD15/NOD2 but not in toll-like receptor 4 (TLR4) Asp299Gly polymorphism in patients with inflammatory bowel disease (IBD) across Europe: Results from the EC-IBD study group. Gastroenterology. 2004, 126 (Suppl S): M1539-
18.
Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu Rev Immunol. 2003, 21: 335-376. 10.1146/annurev.immunol.21.120601.141126.CrossRefPubMed
19.
Hornef MW, Normark BH, Vandewalle A, Normark S: Intracellular recognition of lipopolysaccharide by toll-like receptor 4 in intestinal epithelial cells. J Exp Med. 2003, 198: 1225-1235. 10.1084/jem.20022194.CrossRefPubMedPubMedCentral
20.
Cario E, Podosky DK: Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun. 2000, 68: 7010-7017. 10.1128/IAI.68.12.7010-7017.2000.CrossRefPubMedPubMedCentral
21.
Arbour NC, Lorenz E, Schutte BC: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 2000, 25: 187-191. 10.1038/76048.CrossRefPubMed
22.
Schmitt C, Humeny A, Becker CM, Brune K, Pahl A: Polymorphisms of TLR4: rapid genotyping and reduced response to lipopolysaccharide of TLR4 mutant alleles. Clin Chem. 2002, 48: 1661-1667.PubMed
23.
Erridge C, Stewart J, Poxton IR: Monocytes heterozygous for the Asp299Gly and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signaling. J Exp Med. 2003, 197: 1787-1791. 10.1084/jem.20022078.CrossRefPubMedPubMedCentral
24.
Torok HP, Glas J, Tonenchi L, Mussack T, Folwaczny C: Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the toll-like receptor 4 gene with ulcerative colitis. Clinical immunology. 2004, 112: 85-91. 10.1016/j.clim.2004.03.002.CrossRefPubMed
25.
Gazouli M, Mantzaris G, Kotsinas A, Zacharatos P, Papalambros E, Archimandritis E, Ikonomopoulos J, Gorgoulis VG: Association between polymorphisms in the Toll-like receptor 4, CD14 and CARD15/NOD2 and inflammatory bowel disease in the Greek population. W J Gastroenterol. 2005, 11: 681-685.CrossRef
26.
Franchimont D, Vermeir S, El Housni H, Pierik M, Van Steen K, Gustot T, Quertinmont E, Abramowicz M, Van Gossum A, Devière J, Rutgeerts P: Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp 299Gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut. 2004, 53: 987-992. 10.1136/gut.2003.030205.CrossRefPubMedPubMedCentral
27.
Kornbluth A, Salomon P, Sachar DB: Crohn's disease. Gastrointestinal disease: pathophysiologie/diagnosis/management. Edited by: Sleisenger MH, Fordtran JS. 1993, Philadelphia: Sanders, 2: 1270-302. 5
28.
Gasche C, Scholmerich J, Brynskov J: A simple classification of crohn's disease report of the working party for the world congressess of gastroenterology Vienna 1998. Inflamm Bowel Dis. 1998, 6: 8-15.
29.
Zouiten-Mekki L, Karoui S, Kharrat M, et al: Crohn's disease and polymorphism of heat Shock Protein gene HSP70-2 in Tunisian population. Eur J Gastroenterol Hepatol. 2007, 19 (3): 225-228. 10.1097/01.meg.0000252625.65549.29.CrossRefPubMed
30.
Agnese DM, Calvano JE, Hahm SJ, Coyle SM, Corbett SA, Calvano SE, Lowry SF: Human Toll-Like Receptor 4 Mutations but Not CD14 Polymorphisms Are Associated with an Increased Risk of Gram-Negative Infections. J Inf Diseases. 2002, 186: 1522-5. 10.1086/344893.CrossRef
31.
Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al: Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004, 118: 229-41. 10.1016/j.cell.2004.07.002.CrossRefPubMed
32.
Okayama N, Fujimura K, Suehiro Y, et al: Simple genotype analysis of the Asp299Gly polymorphism of the toll-like receptor-4 gene that is associated with lipopolysaccharide hyporesponsiveness. J Clin Lab Anal. 2002, 16: 56-8. 10.1002/jcla.2075.CrossRefPubMed
33.
Lakatos PL, Lakatos L, Szalay F, Willheim-Polli C, Österreicher C, et al: Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: Phenotype-genotype correlations. World J Gastroenterol. 2005, 11: 1489-1495.CrossRefPubMedPubMedCentral
34.
Leshinsky-silver E, Karban A, Buzhakor E, Fridlander M, Yakir B, Eliaakim R, Reif S, Shaul R, Boaz M, Lev D, Levine A: Is age of onset of Crohn's disease governed by mutations in NOD2/caspase recruitment domains 15 and Toll-like receptor 4? Evaluation of a pediatric cohort. Pediatr Res. 2005, 58: 499-504. 10.1203/01.PDR.0000175640.75468.D6.CrossRefPubMed
35.
Ouburg S, Mallant-Hent R, Crusius JBA, van Bodegraven AA, Mulder CJJ, Linskens R, Pena AS, Morre SA: The toll-like receptor 4 (TLR4) Asp299Gly polymorphism is associated with colonic localisation of Crohn's disease without a major role for the Saccharomyces cerevisiae mannan-LBP-CD14-TLR4 pathway. Gut. 2005, 54: 439-440.PubMedPubMedCentral
36.
Debler J, Schiemann U, Seybold U, et al: Heat-shock protein HSP70-2 genotypes in patients with Crohn's disease: a more severe clinical course with intestinal complications in presence of the PstI-polymorphism. Eur J Med Res. 2003, 27: 120-4.
37.
Esaki M, Furuse M, Matsumoto T, et al: Polymorphism of heat shock protein gene HSP70-2 in Crohn disease: possible genetic marker for two forms of Crohn disease. Scand J Gastroenterol. 1999, 34: 703-707. 10.1080/003655299750025912.CrossRefPubMed
38.
Brand S, Staudinger T, Schnitzler F, Pfennig S, Hofbauer K, Dambacher J, Seiderer J, Tillack C, Konrad A, Crispin A, Goke B, Lohse P, Ochsenkuhn T: The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis. 2005, 11: 645-652. 10.1097/01.MIB.0000168372.94907.d2.CrossRefPubMed
39.
Arnott IDR, Nimmo ER, Drummond HE, et al: NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe?. Genes Immun. 2004, 5: 417-25. 10.1038/sj.gene.6364111.CrossRefPubMed
40.
Nimmo ER, Arnott IDR, Drummond HE, et al: Mutations of toll-like receptor 4 and CD 14 genes are not associated with susceptibility or disease behaviour in inflammatory bowel disease. Gastroenterology. 2003, 124 (Suppl 1): A373-
41.
Oostenbrug LE, De Jong D, Drenth JPH, et al: Lack of association between toll-like receptor 4 haplotype and Asp299Gly polymorphism and susceptibility for inflammatory bowel disease. Gastroenterology. 2003, 124 (Suppl 1): A372-10.1016/S0016-5085(03)81884-X.CrossRef
42.
Noble C, Nimmo E, Gaya D, Russell RK, Satsangi J: Novel susceptibility genes in inflammatory bowel disease. World J Gastroenterol. 2006, 12 (13): 1991-1999.CrossRefPubMedPubMedCentral
43.
Arnott ID, Nimmo ER, Drummond HE, Fennell J, Smith BR, Oostenbrug LE, Drenth JP, de Jong D, Nolte IM, Oosterom E, van Dullemen HM, Linde van der K, te Meerman GJ, Steege van der G, Kleibeuker JH, Jansen PL: Association between Toll like receptor 4 and inflammatory bowel disease. Inflamm Bowel Dis. 2005, 11: 567-575. 10.1097/01.MIB.0000161305.81198.0f.CrossRef
Metadata
Title
Tolllike receptor 4 (TLR4) polymorphisms in Tunisian patients with Crohn's disease: genotype-phenotype correlation
Authors
Lilia Zouiten-Mekki
Maher Kharrat
Sami Karoui
Mariem Serghimi
Monia Fekih
Samira Matri
Lamia Kallel
Jalel Boubaker
Azza Filali
Habiba Chaabouni
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2009
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-9-62

Other articles of this Issue 1/2009

BMC Gastroenterology 1/2009 Go to the issue

Research article

Sensitivity and specificity of plasma disappearance rate of indocyanine green as a prognostic indicator in acute liver failure

Research article

Genetic factors associated with intestinal metaplasia in a high risk Singapore-Chinese population: a cohort study

Research article

No evidence for protective erythropoietin alpha signalling in rat hepatocytes

Research article

Transcript levels of different cytokines and chemokines correlate with clinical and endoscopic activity in ulcerative colitis

Research article

Importance of duodenal bulb biopsies in children for diagnosis of celiac disease in clinical practice

Research article

Efficacy of a 7-day course of furazolidone, levofloxacin, and lansoprazole after failed Helicobacter pylorieradication
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits